Core Viewpoint - Company subsidiaries participated in the national organized procurement for the continuation of drug agreements, with 11 products selected for procurement, indicating a stable revenue stream for the company in the coming years [1][2] Group 1: Procurement Details - The company’s subsidiaries, Hangzhou Kang En Bei Pharmaceutical Co., Ltd. and Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., submitted applications for the national organized procurement continuation [1] - The selected drugs include sustained-release capsules of Tamsulosin Hydrochloride, injectable Piperacillin Sodium and Tazobactam Sodium, and enteric-coated Pantoprazole Sodium, among others [2] Group 2: Financial Impact - The total projected sales revenue from the selected drugs for 2024 is 385.29 million yuan, accounting for 5.91% of the company's total revenue of 6.515 billion yuan [1] - For the first three quarters of 2025, the projected sales revenue from these drugs is 296.15 million yuan, representing 5.95% of the company's revenue of 4.97558 billion yuan [1] Group 3: Pricing Stability - The procurement process is expected to maintain stable or declining prices for the selected drugs, with the procurement quotes for the selected products remaining consistent with their average sales prices in 2025 [2]